Allos Therapeutics Reports Second Quarter 2010 Financial Results
JULY 28, 2010
Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advan ...
JULY 28, 2010
View all News and Events
Allos Therapeutics is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics.

©2010 Allos Therapeutics, Inc.     Home     Site Map     Privacy